These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33467950)

  • 1. Angiotensin receptor neprilysin inhibitor use in patients with left ventricular assist devices: A single-center experience.
    Alishetti S; Braghieri L; Jennings DL; Uriel N; Colombo PC; Yuzefpolskaya M
    Int J Artif Organs; 2022 Jan; 45(1):118-120. PubMed ID: 33467950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System.
    Gjyriqi G; York M; Abuazzam F; Herzog CA; Bangalore S; Lo KB; Sidhu MS; Vaduganathan M; Rangaswami J; Mathew RO
    J Card Fail; 2023 Mar; 29(3):258-268. PubMed ID: 36516938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
    Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
    Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
    Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices.
    Schnettler JK; Roehrich L; Just IA; Pergantis P; Stein J; Mueller M; Mulzer J; Knierim J; Falk V; Potapov FE; Schoenrath F
    J Card Fail; 2021 Dec; 27(12):1328-1336. PubMed ID: 34157393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure medications prescribed at discharge for patients with left ventricular assist devices.
    Shreibati JB; Sheng S; Fonarow GC; DeVore AD; Yancy CW; Bhatt DL; Schulte P; Peterson ED; Hernandez A; Heidenreich PA
    Am Heart J; 2016 Sep; 179():99-106. PubMed ID: 27595684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
    McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
    Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
    Książczyk M; Lelonek M
    Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia.
    Tsai YN; Cheng WH; Chang YT; Hsiao YW; Chang TY; Hsieh YC; Lin YJ; Lo LW; Chao TF; Kuo MJ; Higa S; Chang SL; Chen SA
    J Cardiol; 2021 Oct; 78(4):275-284. PubMed ID: 34059408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials.
    Bao J; Kan R; Chen J; Xuan H; Wang C; Li D; Xu T
    Pharmacol Res; 2021 Jul; 169():105573. PubMed ID: 33766629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction.
    She J; Lou B; Liu H; Zhou B; Jiang GT; Luo Y; Wu H; Wang C; Yuan Z
    ESC Heart Fail; 2021 Dec; 8(6):4607-4616. PubMed ID: 34664407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin Receptor-Neprilysin Inhibition Improves Blood Pressure and Heart Failure Control in Left Ventricular Assist Device Patients.
    Goldberg RL; Freed KE; Klemans N; Fioretti R; Choi CW; Kilic A; Adamo L; Florido R; Sharma K; Gilotra NA; Hsu S
    ASAIO J; 2021 Dec; 67(12):e207-e210. PubMed ID: 33883502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure.
    Kashiwagi Y; Nagoshi T; Kimura H; Tanaka Y; Oi Y; Inoue Y; Ogawa K; Kawai M; Yoshimura M
    ESC Heart Fail; 2023 Jun; 10(3):1860-1870. PubMed ID: 36942494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis.
    Jariwala P; Punjani A; Boorugu H; Madhawar DB
    Indian Heart J; 2021; 73(2):211-213. PubMed ID: 33865520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.